BioNTech’s Bold Leap into Cancer Research Amid Financial Flux: Job Cuts and Strategic Shifts
BioNTech's Q4 2024 earnings dropped to €1.08 per share, surpassing market expectations but reflecting a shift towards cancer treatment. Annual net loss of €700 million occurred as revenues fell from…